Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.35 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13432877 | 0.90 | THRB (0.41) | THRBENPP2PHLPP2PTPN11CYP1A2 | |
| SCHEMBL13432972 | 0.85 | THRB (0.36) | THRBENPP2CYP1A2MEN1HTT | |
| SCHEMBL14159451 | 0.82 | ENPP2 (0.41) | THRBENPP2PHLPP2PTPN11CYP1A2 | |
| SCHEMBL13619110 | 0.81 | THRB (0.40) | THRBENPP2PHLPP2PTPN11CYP1A2 | |
| SCHEMBL13420618 | 0.80 | THRB (0.49) | THRBENPP2PHLPP2CYP1A2MEN1 | |
| SCHEMBL13619097 | 0.80 | THRB (0.43) | THRBENPP2PHLPP2PTPN11CA2 | |
| SCHEMBL13619099 | 0.80 | THRB (0.40) | THRBENPP2PHLPP2PTPN11MEN1 | |
| SCHEMBL13619103 | 0.79 | THRB (0.38) | THRBENPP2 | |
| SCHEMBL13619115 | 0.79 | THRB (0.41) | THRBENPP2PHLPP2PTPN11CYP1A2 | |
| SCHEMBL13619114 | 0.78 | ENPP2 (0.36) | THRBENPP2PHLPP2MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619074-B2 | Reactive dyestuff with N,N-dialkylamino bridge group | EVERLIGHT USA, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090176972-A1 | Novel reactive dyestuff with N,N-dialkylamino bridge group | EVERLIGHT USA, INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176972-A1 | Novel reactive dyestuff with N,N-dialkylamino bridge group | SRM, PADI1, NOS1 | THRB 2058/4885ENPP2 4431/4885PHLPP2 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.